FGF21 gene therapy as treatment for obesity and insulin resistance

Prevalence of type 2 diabetes (T2D) and obesity is increasing worldwide. Currently available therapies are not suited for all patients in the heterogeneous obese/T2D population, hence the need for novel treatments. Fibroblast growth factor 21 (FGF21) is considered a promising therapeutic agent for T...

Descripción completa

Detalles Bibliográficos
Autores principales: Jimenez, Veronica, Jambrina, Claudia, Casana, Estefania, Sacristan, Victor, Muñoz, Sergio, Darriba, Sara, Rodó, Jordi, Mallol, Cristina, Garcia, Miquel, León, Xavier, Marcó, Sara, Ribera, Albert, Elias, Ivet, Casellas, Alba, Grass, Ignasi, Elias, Gemma, Ferré, Tura, Motas, Sandra, Franckhauser, Sylvie, Mulero, Francisca, Navarro, Marc, Haurigot, Virginia, Ruberte, Jesus, Bosch, Fatima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6079533/
https://www.ncbi.nlm.nih.gov/pubmed/29987000
http://dx.doi.org/10.15252/emmm.201708791

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6079533/
https://www.ncbi.nlm.nih.gov/pubmed/29987000
http://dx.doi.org/10.15252/emmm.201708791

Ejemplares similares